Showing 4101-4110 of 9470 results for "".
- HS Patients on Adalimumab Face Higher Risk of Serious Infections than PsO Counterpartshttps://practicaldermatology.com/news/hs-patients-on-adalimumab-face-higher-risk-of-serious-infections-than-pso-counterparts/2483028/Patients with hidradenitis suppurativa (HS) initiating adalimumab face a significantly higher risk of serious, noncutaneous infections requiring hospitalization compared with patients with psoriasis, a new cohort study finds.
- Study: AGE-Inhibitor Cream Improves Skin Tone and Firmness Post-Treatmenthttps://practicaldermatology.com/news/study-age-inhibitor-cream-improves-skin-tone-and-firmness-post-treatment/2483017/An AGE-inhibiting moisturizer significantly improved post-procedure facial appearance following glycolic acid peels or radiofrequency microneedling, particularly among women with skin of color. Researchers for the randomized,
- ASDSA Pushes for Stronger Sun Protection Through SUNucate Legislationhttps://practicaldermatology.com/news/asdsa-pushes-for-stronger-sun-protection-through-sunucate-legislation/2482983/The American Society for Dermatologic Surgery Association (ASDSA) has updated its SUNucate model legislation to expand its reach beyond sunscreen use in schools and school-sponsored events, according to a news release. The SUN
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- GLP-1 Users Drive Growth in Aesthetic Surgeryhttps://practicaldermatology.com/news/glp-1-users-drive-growth-in-aesthetic-surgery/2476140/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- 2025 ASDS Survey: 70% of Consumers Considering Cosmetic Procedureshttps://practicaldermatology.com/news/2025-asds-survey-70-of-consumers-considering-cosmetic-procedures/2475889/Seventy percent of Americans are considering a cosmetic dermatologic procedure, trusting board-certified dermatologists as top influencers in patient decision-making, according to the 2025 Consumer Survey on Cosmetic Dermatologic Procedures by the American Society